Harvoni Tablet, Film Coated
Product Images NDC 61958-1801

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Harvoni (NDC 61958-1801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gilead Sciences, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Harvoni 01)

FDA Label Image

Chemical Structure (Harvoni 02)

FDA Label Image

Harvoni 02a

FDA Label Image

Harvoni 02b

FDA Label Image

Harvoni 02c

FDA Label Image

Harvoni 02d

FDA Label Image

Harvoni 02e

FDA Label Image

Harvoni 02f

FDA Label Image

Harvoni 02g

FDA Label Image

Harvoni 02h

FDA Label Image

Harvoni 02i

FDA Label Image

Harvoni 02j

FDA Label Image

Harvoni 02k

FDA Label Image

Harvoni 02l

FDA Label Image

Harvoni 02m

FDA Label Image

Harvoni 02n

FDA Label Image

Principal Display Panel (28 Tablet Bottle Label)

Harvoni tablets contain 90 mg of ledipasvir and 400 mg of sofosbuvir. They should be stored below 30 °C (86 °F). These tablets should be dispensed only in the original container. Check the package insert for dosage and administration instructions. Harvoni® (ledipasvir, sofosbuvir) tablets should be taken once daily. There is an ALERT box that should not be covered with the pharmacy label. Find out about medicines that should not be taken with Harvoni. Manufactured for Gilead Sciences Inc., Foster City, CA 94404. The text appears to be a description of the drug Harvoni.*

FDA Label Image

Harvoni 04

Harvoni tablets are a medication that consists of 45 mg of ledipasvir and 200 mg of sofosbuvir per tablet. The tablets should be stored below 30°C (86°F) and dispensed only in the original container. The recommended dosage should be referred to in the prescribing information. Harvoni is made in Canada and manufactured for Gilead Sciences, Inc. The medication comes in a package of 28 tablets. Patients should be cautioned about medicines that should not be taken with Harvoni, and the ALERT box should not be covered with a pharmacy label.*

FDA Label Image

Harvoni 05

This is a medication called Harvoni, which comes in the form of oral pellets. Each packet contains 33.75 mg of ledipasvir and 150 mg of sofosbuvir. The medication is manufactured by GILEAD. There is also a note to the pharmacist to not cover the ALERT box with the pharmacy label and to check which medications should not be taken with Harvoni.*

FDA Label Image

Harvoni 06

This is a medicine for oral consumption called Harvoni. It comes in the form of pellets contained in 28 packets, each packet having 45 mg/200 mg of ledipasvir/sofosbuvir. There is a note to the pharmacist not to cover the alert box with the pharmacy label. However, it is not clear what the alert is about due to unclear text recognition.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.